Omeros Corp. (OMER)

14.02
NASDAQ : Health Technology
Prev Close 14.02
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.36 / 27.00
Avg Volume 791.30K
Exchange NASDAQ
Shares Outstanding 48.56M
Market Cap 679.35M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Omeros Corporation Announces Reinstatement Of Pass-Through Status For OMIDRIA®

Omeros Corporation Announces Reinstatement Of Pass-Through Status For OMIDRIA®

Omeros Corporation (NASDAQ: OMER) announced that reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for the company's cataract surgery drug OMIDRIA ® (phenylephrine and ketorolac...

Omeros To Present At The 2018 Cantor Global Healthcare Conference

Omeros To Present At The 2018 Cantor Global Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Cypress Semiconductor, Omeros, Zuora: 'Mad Money' Lightning Round

Cypress Semiconductor, Omeros, Zuora: 'Mad Money' Lightning Round

Jim Cramer weighs in on Cypress Semiconductor, Omeros, Zuora, Kemet, Leidos, Raytheon, and Skyworks Solutions.

Reflecting on 9/11: Cramer's 'Mad Money' Recap (Tuesday 9/11/18)

Reflecting on 9/11: Cramer's 'Mad Money' Recap (Tuesday 9/11/18)

Jim Cramer says he believes we are today better prepared for both the terror and the financial attacks that America endured on 9/11.

Omeros To Present At The Morgan Stanley Global Healthcare Conference

Omeros To Present At The Morgan Stanley Global Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

European Commission Designates OMS721 As An Orphan Medicinal Product For Treatment In Hematopoietic Stem Cell Transplantation

European Commission Designates OMS721 As An Orphan Medicinal Product For Treatment In Hematopoietic Stem Cell Transplantation

Omeros Corporation (Nasdaq: OMER) today announced that the European Commission (EC) has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union (EU) for treatment in hematopoietic stem cell transplantation (HSCT).

Notable Friday Option Activity: OMER, SQ, VTL

Notable Friday Option Activity: OMER, SQ, VTL

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 2,615 contracts have traded so far, representing approximately 261,500 underlying shares. That amounts to about 58.2% of OMER's average daily trading volume over the past month of 449,185 shares.

Omeros To Present At The 2018 Wedbush PacGrow Healthcare Conference

Omeros To Present At The 2018 Wedbush PacGrow Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Omeros Corporation Reports Second Quarter 2018 Financial Results

Omeros Corporation Reports Second Quarter 2018 Financial Results

Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2018, which include: 2Q 2018 total and OMIDRIA ® revenues were $1.

Omeros Corporation To Announce Second Quarter 2018 Financial Results On August 9, 2018

Omeros Corporation To Announce Second Quarter 2018 Financial Results On August 9, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes.

Omeros Hires Former Sanofi Global Development Head As Chief Medical Officer

Omeros Hires Former Sanofi Global Development Head As Chief Medical Officer

Omeros Corporation (Nasdaq: OMER) today announced that Eckhard Leifke, M.D.

Sandoz Amends ANDA To Not Seek Approval For Generic Version Of OMIDRIA Until Patents For Omeros' Drug Expire

Sandoz Amends ANDA To Not Seek Approval For Generic Version Of OMIDRIA Until Patents For Omeros' Drug Expire

Omeros Corporation (Nasdaq: OMER) today announced that its patent infringement lawsuit against Sandoz Inc.

Interesting OMER Put And Call Options For February 2019

Interesting OMER Put And Call Options For February 2019

Investors in Omeros Corp saw new options begin trading this week, for the February 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 205 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Omeros' OMS721 Receives European Orphan Drug Designation Positive Opinion For Treatment In Hematopoietic Stem Cell Transplantation

Omeros' OMS721 Receives European Orphan Drug Designation Positive Opinion For Treatment In Hematopoietic Stem Cell Transplantation

Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency's (EMA's) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell...

Omeros Corporation Initiates Sales Of OMIDRIA® In Europe

Omeros Corporation Initiates Sales Of OMIDRIA® In Europe

Omeros Corporation (NASDAQ: OMER) today announced initial sales of OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1%/0.

Omeros Initiates Dosing In Phase 1 Clinical Trial For OMS527 Targeting Addiction

Omeros Initiates Dosing In Phase 1 Clinical Trial For OMS527 Targeting Addiction

Omeros Corporation (NASDAQ: OMER) today announced that the first cohort of subjects has been dosed in the Company's Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros' OMS527 program broadly targeting addictions and...

Omeros Obtains Approval To Initiate Phase 1 Clinical Trial For Its OMS527 Addiction Treatment

Omeros Obtains Approval To Initiate Phase 1 Clinical Trial For Its OMS527 Addiction Treatment

Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company's OMS527 program.

Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Lupin

Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Lupin

Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd.

Interesting OMER Put And Call Options For July 20th

Investors in Omeros Corp saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

Omeros Corporation Reports First Quarter 2018 Financial Results

Omeros Corporation Reports First Quarter 2018 Financial Results

Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018, which include: 1Q 2018 total and OMIDRIA ® revenues were $1.

Omeros Corporation To Announce First Quarter 2018 Financial Results On May 10, 2018

Omeros Corporation To Announce First Quarter 2018 Financial Results On May 10, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its first quarter 2018 financial results for the period ended March 31, 2018, on Thursday, May 10, 2018, after the market closes.

First Week Of June 15th Options Trading For Omeros (OMER)

Investors in Omeros Corp saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

Additional Clinical Studies Supporting The Benefits Of OMIDRIA® Presented At The American Society Of Cataract And Refractive Surgery And American Society Of Ophthalmic Administrators Annual Meeting

Additional Clinical Studies Supporting The Benefits Of OMIDRIA® Presented At The American Society Of Cataract And Refractive Surgery And American Society Of Ophthalmic Administrators Annual Meeting

Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.

2 Small Biotechs That Continue to Look Good

2 Small Biotechs That Continue to Look Good

Several biotech names held up well or even had solid advances during last week's broad market selloff.

2 Small Biotechs That Look Good

2 Small Biotechs That Look Good

Achaogen and Omeros both rose as the Dow was losing 724 points.

New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores

New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores

Despite lobbying hard for changes, the pharmaceutical industry is going to cover more costs regarding Medicare Part D in the $1.3 trillion budget that needs to pass by Friday.

TheStreet Quant Rating: D- (Sell)